133 related articles for article (PubMed ID: 31981398)
1. In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.
Yu J; Ragueneau-Majlessi I
Clin Transl Sci; 2020 Jul; 13(4):693-699. PubMed ID: 31981398
[TBL] [Abstract][Full Text] [Related]
2. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
Yu J; Wang Y; Ragueneau-Majlessi I
Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
[TBL] [Abstract][Full Text] [Related]
4. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
6. Usage of In Vitro Metabolism Data for Drug-Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration.
Lee J; Yang Y; Zhang X; Fan J; Grimstein M; Zhu H; Wang Y
J Clin Pharmacol; 2021 Jun; 61(6):782-788. PubMed ID: 33460193
[TBL] [Abstract][Full Text] [Related]
7. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo.
Zhou T; Arya V; Zhang L
J Clin Pharmacol; 2019 Aug; 59(8):1049-1060. PubMed ID: 30924955
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
[TBL] [Abstract][Full Text] [Related]
9. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
[TBL] [Abstract][Full Text] [Related]
10. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
11. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
Sosnik A
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
14. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
15. Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval.
Zimmerman K; Putera M; Hornik CP; Brian Smith P; Benjamin DK; Mulugeta Y; Burckart GJ; Cohen-Wolkowiez M; Gonzalez D
Clin Ther; 2016 Sep; 38(9):1995-2005. PubMed ID: 27364807
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
Eckert JC
Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
[TBL] [Abstract][Full Text] [Related]
17. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
18. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
Fleisher B; Unum J; Shao J; An G
J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
[TBL] [Abstract][Full Text] [Related]
19. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
20. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
